CR20190112A - Procedimiento de manejo de dismenorrea y dolor menstrual - Google Patents

Procedimiento de manejo de dismenorrea y dolor menstrual

Info

Publication number
CR20190112A
CR20190112A CR20190112A CR20190112A CR20190112A CR 20190112 A CR20190112 A CR 20190112A CR 20190112 A CR20190112 A CR 20190112A CR 20190112 A CR20190112 A CR 20190112A CR 20190112 A CR20190112 A CR 20190112A
Authority
CR
Costa Rica
Prior art keywords
estetrol
dysmenorrhea
compounds
management
mitigating
Prior art date
Application number
CR20190112A
Other languages
English (en)
Spanish (es)
Inventor
Glwadys Rausin
Maud Jost
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/076104 external-priority patent/WO2018065076A1/en
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of CR20190112A publication Critical patent/CR20190112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR20190112A 2016-08-05 2017-08-07 Procedimiento de manejo de dismenorrea y dolor menstrual CR20190112A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16183025 2016-08-05
PCT/EP2016/076104 WO2018065076A1 (en) 2016-10-28 2016-10-28 Method for the management of dysmenorrhea and menstrual pain
PCT/EP2017/069908 WO2018024912A1 (en) 2016-08-05 2017-08-07 Method for the management of dysmenorrhea and menstrual pain

Publications (1)

Publication Number Publication Date
CR20190112A true CR20190112A (es) 2019-06-25

Family

ID=56609757

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190112A CR20190112A (es) 2016-08-05 2017-08-07 Procedimiento de manejo de dismenorrea y dolor menstrual

Country Status (12)

Country Link
US (2) US20190167700A1 (OSRAM)
JP (2) JP6557298B2 (OSRAM)
KR (1) KR102712911B1 (OSRAM)
AU (1) AU2022231672B2 (OSRAM)
BR (1) BR112019002203A2 (OSRAM)
CA (1) CA3178291A1 (OSRAM)
CO (1) CO2019000672A2 (OSRAM)
CR (1) CR20190112A (OSRAM)
MX (1) MX2022011436A (OSRAM)
PE (1) PE20190739A1 (OSRAM)
PH (1) PH12019500172B1 (OSRAM)
WO (1) WO2018024912A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
KR102780201B1 (ko) * 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN111683664A (zh) * 2018-02-07 2020-09-18 埃斯特拉私人有限责任公司 具有降低的心血管作用的避孕组合物
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CL2021001762A1 (es) * 2021-07-01 2022-01-21 Univ Pontificia Catolica Chile Uso del estetrol como tratamiento para la endometriosis
EP4134082A1 (en) * 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception
US12233074B2 (en) 2022-02-10 2025-02-25 Estetra Srl Contraceptive methods with improved pearl index
CN120752042A (zh) * 2023-02-23 2025-10-03 埃斯特拉有限责任公司 用于缓解或治疗疼痛的包含雌四醇和屈螺酮的组合物
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
CA1306950C (en) 1987-04-10 1992-09-01 Alec D. Keith Buccal administration of estrogens
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
JPH03237557A (ja) 1990-02-14 1991-10-23 Oki Electric Ind Co Ltd ニューラルネットワークシミュレータ及び計算機システム
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
AU2103495A (en) 1994-08-04 1996-03-04 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
BR9813808A (pt) 1997-12-19 2002-05-28 Smithkline Beecham Corp Processo para produção de comprimidos para dispersão na mordida
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
PL202999B1 (pl) 1999-12-02 2009-08-31 Organon Nv Androgeny zawierające pierścień cyklopropanowy w pozycjach 14, 15 i zastosowanie takich androgenów
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EE05533B1 (et) 2000-01-18 2012-04-16 Schering Aktiengesellschaft Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US8048869B2 (en) 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
DK1390042T3 (da) 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
EP1390041B1 (en) 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
CA2467222C (en) 2001-11-15 2010-06-08 Herman Jan Tijmen Coelingh Bennink Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
CA2476940C (en) 2002-02-21 2011-11-01 Herman Jan Tijmen Coelingh Bennink Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US7943604B2 (en) 2002-06-11 2011-05-17 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
CN1691947B (zh) 2002-06-11 2011-11-23 潘塔希生物科学股份有限公司 雌激素成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述雌激素成分的药物组合物
CA2492287C (en) 2002-07-12 2011-12-13 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
RS20050184A (sr) 2002-08-28 2007-11-15 Robert Casper Režim zamene estrogena
CN100528167C (zh) 2002-10-23 2009-08-19 潘塔希生物科学股份有限公司 用于治疗癌症的包含雌四醇衍生物的药物组合物
AU2003278434A1 (en) 2002-11-05 2004-06-07 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
ATE469165T1 (de) 2002-11-08 2010-06-15 Pantarhei Bioscience Bv Synthese von oestetrol aus von oestron abgeleiteten steroiden
DK1624878T3 (da) 2003-05-22 2007-01-08 Pantarhei Bioscience Bv Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte
EP1673071A1 (en) 2003-09-29 2006-06-28 Novo Nordisk Femcare AG Improved stability of progestogen formulations
PT1670440E (pt) 2003-09-29 2014-08-22 Novo Nordisk Femcare Ag Formulações hrt
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
PT1755562E (pt) 2004-05-28 2013-12-26 Richter Gedeon Nyrt Contraceptivo contendo ácido fólico
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
US8808735B2 (en) 2005-02-03 2014-08-19 Takeda Nycomed As Fast wet-massing method for the preparation of calcium-containing compositions
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
JP5268635B2 (ja) 2005-05-26 2013-08-21 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング １７β−ＨＳＤ１及びＳＴＳインヒビター
BRPI0612586A2 (pt) 2005-06-29 2010-11-23 Wyeth Corp formulações de estrogênios conjugados e bazedoxifeno
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
CA2636638C (en) 2006-01-09 2014-02-18 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
ES2352547T3 (es) 2006-01-09 2011-02-21 Pantarhei Bioscience B.V. Método para tratar un trastorno vascular agudo.
CA2640520C (en) 2006-03-02 2014-04-22 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
ES2659316T3 (es) 2006-06-08 2018-03-14 Allergan Pharmaceuticals International Limited Procedimientos para administrar formas de dosificación sólidas de etinilestradiol y profármacos del mismo con biodisponibilidad mejorada
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CA2665788A1 (en) 2006-07-06 2008-01-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
CA2670544A1 (en) 2006-11-29 2008-06-05 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
CA2674776A1 (en) 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
US8236785B2 (en) 2007-01-08 2012-08-07 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
PE20081632A1 (es) 2007-01-12 2008-12-10 Wyeth Corp Composiciones de tableta en tableta
CN102014924B (zh) 2007-06-21 2012-07-18 潘塔希生物科学股份有限公司 用雌激素治疗胎粪吸入综合征
WO2009011576A1 (en) 2007-07-19 2009-01-22 Pantarhei Bioscience B.V. Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
EP2210591B1 (en) 2009-01-26 2016-03-30 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
NZ597239A (en) 2009-06-23 2013-07-26 Bayer Pharma AG Pharmaceutical composition for emergency contraception
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
US8901185B2 (en) 2010-04-12 2014-12-02 Universite Claude Bernard Lyon I Hybrid organic-inorganic material constituted by a silica network having photochromic agents and optical power limiting agents as a doping agent in the material
MX356702B (es) 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
EP2646003B1 (en) 2010-12-02 2020-06-03 Adare Pharmaceuticals, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
CL2013003435A1 (es) 2011-06-01 2014-08-01 Estetra Sprl Proceso de preparacion de intermediarios de estetrol utilizando catalizadores de paladio y grupos protectores acilantes o sililantes; y uso de dicho proceso para preparar estetrol.
PT2714710T (pt) 2011-06-01 2016-07-12 Estetra Sprl Processo para a produção de intermediários de estetrol
AU2012264601C1 (en) 2011-06-01 2018-01-25 Estetra Srl Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
WO2013012326A1 (en) 2011-07-19 2013-01-24 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (dhea)
HRP20170797T1 (hr) 2011-08-11 2017-08-11 Estetra S.P.R.L. Primjena estetrola kao hitnog kontraceptiva
NZ620897A (en) 2011-09-16 2016-07-29 Ferring Bv A fast dissolving pharmaceutical composition
EP2764008B1 (en) 2011-10-07 2016-08-17 Estetra S.P.R.L. Process for the production of estetrol
WO2013090117A1 (en) 2011-12-13 2013-06-20 Arstat, Inc. A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
US20140341326A1 (en) 2013-05-20 2014-11-20 Qualcomm Incorporated Channel estimation with discontinuous pilot signals
JP2016520590A (ja) 2013-05-21 2016-07-14 プレディクティヴ セラピューティクス, リミテッド ライアビリティー カンパニーPredictive Therapeutics, LLC 治療薬および使用法
CA2924255C (en) 2013-09-18 2022-11-22 Crystal Pharma, S.A.U. Process for the preparation of estetrol
US12274276B2 (en) 2013-10-03 2025-04-15 Altria Client Services Llc Dissolvable-chewable tablet
KR102265150B1 (ko) * 2013-12-12 2021-06-16 에스테트라 에스.피.알.엘. 에스테트롤 성분을 함유하는 구강 붕해성 고체 투여 단위
WO2016023009A1 (en) 2014-08-07 2016-02-11 Wake Forest University Health Sciences Compositions and methods for clearing a biological sample
EP3200802B1 (en) 2014-09-29 2023-07-12 The Regents of The University of California Compositions and methods for maintaining cognitive function
WO2016187269A1 (en) 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
MX389310B (es) 2015-06-23 2025-03-20 Laboratorios Leon Farma Sa Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
CN111683664A (zh) 2018-02-07 2020-09-18 埃斯特拉私人有限责任公司 具有降低的心血管作用的避孕组合物
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Also Published As

Publication number Publication date
KR20220144885A (ko) 2022-10-27
KR102712911B1 (ko) 2024-10-04
US11896602B2 (en) 2024-02-13
AU2022231672B2 (en) 2024-03-07
US20230041304A1 (en) 2023-02-09
JP6557298B2 (ja) 2019-08-07
JP2018165263A (ja) 2018-10-25
JP7177313B2 (ja) 2022-11-24
WO2018024912A1 (en) 2018-02-08
PH12019500172B1 (en) 2024-02-28
CA3178291A1 (en) 2018-04-12
MX2022011436A (es) 2022-11-14
JP2019163318A (ja) 2019-09-26
PH12019500172A1 (en) 2019-07-29
AU2022231672A1 (en) 2022-10-06
PE20190739A1 (es) 2019-05-23
CO2019000672A2 (es) 2019-04-30
BR112019002203A2 (pt) 2019-05-14
US20190167700A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
CR20190112A (es) Procedimiento de manejo de dismenorrea y dolor menstrual
MY205032A (en) Method for the management of dysmenorrhea and menstrual pain
MX2018008011A (es) Composicion y metodo para el crecimiento del cabello.
MX2019005737A (es) Composicion farmaceutica para prevenir o tratar el cancer de cerebro que incluye polimorfocristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo.
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CL2018000429A1 (es) Moduladores de la expresión de kras
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
WO2014194254A9 (en) Treatment of cancers using pi3 kinase isoform modulators
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
NZ722326A (en) Tricyclic compounds as anticancer agents
MX2016016115A (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX353096B (es) Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
MX2018002344A (es) Metodo para tratar el cancer.
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
NZ710602A (en) Methods for reducing pyrogenicity in a seaweed extract
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
MX2017010422A (es) Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes.
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
SA522432999B1 (ar) C-17 مركبات تراي تريبينويد تخليقية ذات مجموعات استبدال اساسها نيتروجين عند وطرق استخدامها
CL2019001338A1 (es) Preparación cosmética de viscosidad mejorada para el tratamiento de las fibras queratínicas, proceso para el aumento de la viscosidad de una preparación cosmética, uso de ingredientes modificadores de la viscosidad y método de tratamiento de las fibras queratínicas.